American Society of Hematology, 2025 (ASH)7 - 9 December 2025
From efficacy to experience: 52-week patient-reported outcomes with Mim8 in adolescents and adults with Hemophilia A with or without inhibitors (FRONTIER2)
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.